BCL2 and B-cell chronic lymphocytic leukemia: Amongst them, the BCL-2 specific BH3-mimetic venetoclax5 shows considerable clinical promise and is approved for the treatment of chronic lymphocytic leukaemia (CLL)6 and in combination therapy to treat acute myeloid leukaemia (AML)7,8.